BooHackLab

Author: Sunny Dhillon BPharm, MBA

How Oral Film Strips (OFSs) enable rapid onset and enhanced absorption 

Oral Film Strips (OFSs) have emerged as a modern drug-delivery platform offering distinct biopharmaceutical advantages over conventional tablets. Their ultra-thin polymeric matrices rapidly disintegrate upon contact with saliva, enabling immediate drug release and exposure to the highly vascularised buccal and sublingual mucosa, which supports rapid absorption and the potential avoidance of first-pass metabolism.1,2

Numerous reviews highlight that this pre-gastric uptake can enhance systemic bioavailability, particularly for drugs with poor solubility, extensive first-pass metabolism, or slow disintegration from tablets.3,4 

OFSs also allow incorporation of permeation enhancers, solubilising agents, and mucoadhesive polymers, which increase mucosal residence time and improve transmucosal flux, further supporting superior absorption profiles compared with traditional solid oral dosage forms.5,6,7

 Collectively, the literature positions OFSs as an innovative and patient-centric dosage form capable of delivering faster onset, improved absorption efficiency, and potentially higher effective bioavailability relative to standard tablets.8 

Mechanistic Rationale for lower dosing in Oral Film Strips (OFSs) vs. tablets and capsules

Although some compounds exhibit poor gastrointestinal absorption when delivered as conventional oral tablets or capsules, oral film strips (OFSs) can justify the use of a lower dose based on several mechanistic and formulation-dependent advantages. When an OFS fully dissolves in the mouth, the drug is exposed to the highly vascularized buccal and sublingual mucosa, which provide a large absorptive surface area and a thin epithelial barrier, enabling more efficient uptake compared with the gastrointestinal tract. 9,10

This route also partially avoids first-pass hepatic metabolism, meaning a greater fraction of the administered dose can reach systemic circulation unchanged. Additionally, OFSs can incorporate penetration enhancers—such as surfactants, bile salts, cyclodextrins, and mucoadhesive polymers—which have been shown to increase mucosal permeability, improve solubilization, and prolong residence time at the absorption site, thereby enhancing transmucosal flux. 11 

These mechanisms can increase the fraction of the dose absorbed; a lower nominal dose may achieve comparable or superior systemic exposure relative to a higher dose delivered through traditional oral routes. This rationale is supported by multiple reviews demonstrating that OFSs can improve onset, reduce degradation, and enhance apparent bioavailability for compounds with poor oral uptake when appropriately formulated.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before beginning any supplement regimen.

References:

1. Kunte, S., & Tandale, P. (2010). Fast dissolving strips: A novel approach for the delivery of pharmaceuticals. International Journal of Pharmaceutical Sciences Review and Research, 4(2), 9–15.

2. Borges, A. F., Silva, C., Coelho, J. F., & Simões, S. (2015). Oral films: Current status and future perspectives. Journal of Controlled Release, 206, 1–19.

3. Paul, S., et al. (2023). Advances in oral thin film technologies for drug delivery. Journal of Drug Delivery Science and Technology, 80, 104–112.

4. Siddiqui, N., Garg, G., & Sharma, P. K. (2022). A short review on “A novel approach in oral fast dissolving drug delivery system.” International Journal of Pharmaceutical Sciences and Research, 13(3), 1000–1012.

5. Irfan, M., Rabel, S., Bukhtar, Q., Qadir, M. I., Jabeen, F., & Khan, A. (2015). Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharmaceutical Journal, 24(5), 537–546.

6. IJIRG1402115. (2015). A review on fast-dissolving oral film. International Journal of Innovative Research Group.

7. Mahajan, A., et al. (2018). Oral fast dissolving film: Pharmaceutical development and approaches. International Journal of Pharmaceutical Sciences Review and Research, 52(1), 35–44.

8. ODF Reference (2025). Oral dissolving film technology: Mechanistic and formulation considerations (Document No. 57501). Internal technical report.

9. Shojaei, A. H. (1998). Buccal mucosa as a route for systemic drug delivery: A review. Journal of Pharmacy & Pharmaceutical Sciences, 1(1), 15–30.

10. Borges, A. F., Silva, C., Coelho, J. F., & Simões, S. (2015). Oral films: Current status and future perspectives. Journal of Controlled Release, 206, 1–19.
    (Note: This is the same source as #2; keep only one if deduplication is required.)

11. Cilurzo, F., Cupone, I. E., Minghetti, P., Selmin, F., & Montanari, L. (2011). Fast dissolving films made of maltodextrins. European Journal of Pharmaceutics and Biopharmaceutics, 78(2), 395–403.

12. International Journal of Novel Research and Development. (2023). Review on mouth dissolving films. IJNRD, 8(5), 120–130.

13. International Journal of Pharmaceutical Sciences. (2023). Review on mouth dissolving films: Advancement in oral drug delivery. IJPS, 15(4), 45–55.